What is the ROE (Return on Equity) of Medincell this year?
The ROE of Medincell this year is 0.76 undefined.
Medincell ROE 2024
Medincell ROE
0.76
Medincell Dividend yield
Ticker
MEDCL.PA
ISIN
FR0004065605
WKN
A2N6VA
In 2024, Medincell's return on equity (ROE) was 0.76, a -59.2% increase from the 1.86 ROE in the previous year.
Medincell Aktienanalyse
What does Medincell do?
Medincell SA is a leading biotechnology company based in Montpellier, France, specializing in the development and manufacturing of innovative drugs based on its proprietary Intellisome® technology platform. The company was founded in 1999 by Dr. Christophe Douat and has since built an impressive portfolio of products and services. Medincell's business model is based on the development and manufacturing of extended-release drugs through the integration of drugs into the Intellisome® technology platform. This is a novel concept based on the use of polymers that are capable of controlling and slowing down the release of drugs. This allows medications to be administered in a specific dosage and duration, providing greater effectiveness and tolerability for the patient. Medincell has several business areas, including the development of drugs for the treatment of central nervous system (CNS) disorders, including schizophrenia, depression, and chronic pain. The company is also working on the development of drugs for the treatment of infectious diseases and cancer, as well as the development of new technologies for drug manufacturing. Medincell's products include a range of drugs, including Long-Acting Risperidone (a depot preparation for the treatment of schizophrenia), Long-Acting Cabergoline (for the treatment of Parkinson's), and Long-Acting Naltrexone (for the treatment of alcohol and drug addiction). The company also has partnerships with other pharmaceutical companies such as Pierre Fabre, Sanofi, Janssen, and Pfizer for the development of products based on its Intellisome® technology platform. Another important area of Medincell is its service for drug development based on the Intellisome® technology platform. The company offers customers comprehensive support in the development, manufacturing, and approval of extended-release drugs. Customers can choose from a wide range of services, ranging from the identification of active ingredients to the implementation of clinical trials. Overall, Medincell has achieved impressive success in the launch of its products and services based on the Intellisome® technology platform. The company has won several awards for its innovative products and services in the pharmaceutical industry, including the Innovation Award from the European Society of Clinical Microbiology and Infectious Diseases in 2018 and the Excellence in Specialty Pharmaceuticals Award from BioPharm America in 2019. In summary, Medincell SA is a leading company in the biotechnology industry specializing in the development and manufacturing of extended-release drugs based on its Intellisome® technology platform. With an impressive range of products and services and partnerships with several renowned pharmaceutical companies, the company has a promising future as a key player in the pharmaceutical industry. Medincell ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Medincell's Return on Equity (ROE)
Medincell's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Medincell's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Medincell's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Medincell’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Medincell Stock
How has the Return on Equity (ROE) of Medincell developed compared to the previous year?
The ROE of Medincell has increased by -59.2% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Medincell?
A high ROE indicates that Medincell generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Medincell?
A low ROE can indicate that Medincell is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Medincell affect the company?
A change in ROE (Return on Equity) of Medincell can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Medincell?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Medincell?
Some factors that can influence Medincell's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Medincell pay?
Over the past 12 months, Medincell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medincell is expected to pay a dividend of 0 EUR.
What is the dividend yield of Medincell?
The current dividend yield of Medincell is .
When does Medincell pay dividends?
Medincell pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Medincell?
Medincell paid dividends every year for the past 0 years.
What is the dividend of Medincell?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Medincell located?
Medincell is assigned to the 'Health' sector.
Wann musste ich die Aktien von Medincell kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Medincell from 5/16/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.
When did Medincell pay the last dividend?
The last dividend was paid out on 5/16/2024.
What was the dividend of Medincell in the year 2023?
In the year 2023, Medincell distributed 0 EUR as dividends.
In which currency does Medincell pay out the dividend?
The dividends of Medincell are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Medincell stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Medincell
Our stock analysis for Medincell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medincell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
